Sanofi to buy Dynavax for US$2.2 billion to add shingles vaccine
Sanofi agreed to buy Dynavax Technologies for about US$2.2 billion to expand its vaccines business with a shot for hepatitis B and an experimental shingles inoculation.
Sanofi will pay US$15.50 a share in cash for the Emeryville, California-based company, according to a statement on Wednesday (Dec 24). The price is 39% above Tuesday’s closing level for Dynavax.
The agreement isn’t expected to have any impact on Sanofi’s financial guidance for 2025, the company said. The company expects to complete the acquisition in the first quarter of 2026. BLOOMBERG
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Originally published by businesstimes.com.sg. Syndicated material does not necessarily reflect the views of Grazia British.
More Culture
Don’t Pull Out of Germany
Merz’s stupidity is no excuse for a stupid response. Source link
Step inside the gorgeous, futuristic offices of Vast, the startup designing the next-gen space station
A tall baobab tree greets people inside the Long Beach, California, headquarters of Vast, an aerospace company that is building the space station of the future. It’s planted beneath a…
5 ways high-performing teams stay calm when everything’s on fire
When markets swing, plans break, inboxes explode, and everyone starts saying the situation is “unprecedented” again, most teams do what humans have always done under pressure: they grip…
Confused Trump Openly Admits Plot to Rig Midterms as Polls Turn Brutal
Last week, the Supreme Court gutted protections against racial gerrymandering, and Donald Trump is already urging Republicans to seize on it. Trump unleashed a Truth Social rant on Monday…